3-bromo-2-methyl-5-(3-trifluoromethylphenyl)thiophene | 864362-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-bromo-2-methyl-5-(3-trifluoromethylphenyl)thiophene
• 英文别名: 3-bromo-2-methyl-5-[3-(trifluoromethyl)phenyl]thiophene
• CAS: 864362-75-4
• 化学式: C₁₂H₈BrF₃S
• 分子量: 321.161
• InChiKey: DYWJJIRNDHKDKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-bromo-2-methyl-5-(3-trifluoromethylphenyl)thiophene 在 正丁基锂 作用下， 以 正己烷 为溶剂， 生成 5-[3-(Trifluoromethyl)phenyl]-1,1,2,2,3,3-hexafluoro-6a,6b-dimethyl-1,2,6a,6b-tetrahydro-3H-6-thiadicyclopenta[a,c]phenanthrene
  参考文献：
  名称：

  New photochromic diarylethenes bearing a condensed aromatics moiety

  摘要：

  A new class of diarylethenes based on a hybrid structure of naphthalene and thiophene have been developed and their properties including photochromism, fatigue resistance, and fluorescence have been investigated. The condensed aromatic naphthalene was connected directly to the central cyclopentene ring as an aryl moiety and available to participate in the photoinduced cyclization reaction. All of these compounds have exhibited good photochromism, notable fatigue resistance, and obvious fluorescence photo-switches in both solution and polymer matrix. Nevertheless, significantly different properties have been observed among these diarylethenes, which may be attributed to the effect of different substituent groups. Compared with the analogs bearing other six-membered aryl unit, the naphthalene moiety is more conducive, which leads to higher molar absorption coefficient and blue shift of the absorption maximum. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.04.063
• 作为产物：
  描述：

  间溴三氟甲苯 、 4-溴-5-甲基噻吩-2-硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 16.0h， 以84%的产率得到3-bromo-2-methyl-5-(3-trifluoromethylphenyl)thiophene
  参考文献：
  名称：

  一种新型不对称光致变色二芳基乙烯的合成，晶体结构和光电性能。

  摘要：

  合成了一种新的不对称光致变色二芳基乙烯1-（2-甲基-5-苯基-3-噻吩基）-2- [2-甲基-5-（3-三氟甲基苯基）-3-噻吩基]全氟环戊烯（1a）通过单晶X射线衍射分析确定结构。详细研究了其光学和电化学性质，包括溶液和固态（PMMA膜和单晶相）的光致变色反应性，荧光和电化学性质。该化合物即使在通过光照射的单晶相中也显示出优异的光致变色性。在乙腈中，二芳基乙烯1的开环异构体在300 nm处激发时在470 nm处显示出较强的荧光，并且其发射强度随313 nm光照射时的光致变色而降低。它的闭环异构体几乎没有荧光。通过循环伏安法研究了二芳基乙烯的电化学性能，计算了其HOMO和LUMO能级。

  DOI：

  10.1016/j.saa.2007.10.026

文献信息

• A Novel Indole-Containing Diarylethene: Synthesis, Crystal Structure and Photochromism
  作者：Chunhong Zheng、Guanming Liao、Congbin Fan、Renjie Wang、Shouzhi Pu

  DOI：10.3184/174751917x14981229444839

  日期：2017.7

  An indole-containing diarylethene with a trifluoromethyl function at the meta-position of the phenyl group attached to the thiophene moiety was synthesised. Its structure was determined by single-crystal X-ray diffraction analysis and its photochemical properties in solution and in the single crystalline phases were studied. The compound showed relatively high fluorescent modulation efficiency and

  合成了在连接到噻吩部分的苯基的间位具有三氟甲基官能团的含吲哚的二芳基乙烯。通过单晶X射线衍射分析确定了其结构，并研究了其在溶液和单晶相中的光化学性质。该化合物显示出相对较高的荧光调制效率和环化量子产率。
• Heterocyclic derivative and use thereof
  申请人：Matsunaga Nobuyuki

  公开号：US08461348B2

  公开（公告）日：2013-06-11

  The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

  本发明旨在提供一种具有优越的药理作用、物理化学性质等，并且可用作sGC激活药物或预防和/或治疗高血压、缺血性心脏病、心力衰竭、肾脏疾病、动脉硬化性疾病、心房颤动、肺动脉高压、糖尿病、糖尿病并发症、代谢综合征、周围动脉阻塞性疾病、勃起功能障碍等疾病的药剂的化合物。该sGC激活药物包含以下式子（II）所表示的化合物或其盐作为活性成分，其中每个符号如规范所定义。
• HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Matsunaga Nobuyuki

  公开号：US20110028493A1

  公开（公告）日：2011-02-03

  The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.

  本发明旨在提供一种具有优异的药理作用、物理化学性质等，并且可用作sGC激活药物、高血压、缺血性心脏病、心力衰竭、肾脏疾病、动脉硬化疾病、心房颤动、肺动脉高压、糖尿病、糖尿病并发症、代谢综合征、周围动脉阻塞、勃起功能障碍等疾病的预防和/或治疗剂的化合物。其中，所述化合物为式（II）所表示的化合物或其盐，作为活性成分的sGC激活药物。式（II）中，各符号如规范中定义的。
• US8461348B2
  申请人：——

  公开号：US8461348B2

  公开（公告）日：2013-06-11